Evidence map›Paper›PMID 38668903›Full record

ArticleEJNMMI research2024

Biodistribution and radiation dosimetry of [

Andreas Rinscheid, Alexander Gäble, Georgine Wienand, Alexander Dierks, Malte Kircher, Thomas Günther, Marianne Patt, Ralph A Bundschuh, Constantin Lapa, Christian H Pfob

Open access · goldAbstract read
In one paragraph

Article in EJNMMI research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Radionuclides Landscape in Prostate Cancer Theranostics.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Andreas Rinscheid *Medical Physics and Radiation Protection, University Hospital Augsburg, Augsburg, Germany.
Alexander Gäble *Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Georgine WienandNuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Alexander DierksNuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Malte KircherNuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Thomas GüntherMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, Palo Alto, CA, USA.
Marianne PattNuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Ralph A BundschuhNuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Constantin Lapa *Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany. Constantin.Lapa@uk-augsburg.de.ORCID http://orcid.org/0000-0001-7536-2207
Christian H Pfob *Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.ORCID http://orcid.org/0000-0003-2989-5883
University of Augsburg · DEStanford University · USTechnische Hochschule Augsburg · DEUniversity Hospital Augsburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn patients with prostate cancer (PCa), imaging with gastrin-releasing peptide receptor (GRPR) ligands is an alternative to PSMA-targeted tracers, particularly if PSMA expression is low or absent. [

resultsNo adverse pharmacologic effects were observed. Injection of [

conclusion[

Indexed as

BombesinGRPRPETProstate cancerTheranostics

Identifiers

PMID38668903
PMCPMC11052738
OpenAlexW4395675436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.